Zyla Life Sciences Finite-Lived Intangible Asset, Expected Amortization, Year Three
Zyla Life Sciences had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $13.59 million as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2020-03-26
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $13.59M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $1.09M.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $1.15M.
- 2016-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $2.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Three |
|---|---|
| 2019-12-31 | $13.59M 10-K · filed 2020-03-26 |
| 2018-12-31 | $1.09M 10-K · filed 2019-03-29 |
| 2017-12-31 | $1.15M 10-K · filed 2018-03-16 |
| 2016-12-31 | $2.00M 10-K · filed 2017-03-13 |
| 2015-12-31 | $2.00M 10-K · filed 2016-03-11 |